Intercept to Present at Upcoming Conference
March 13 2018 - 5:00PM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a
biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat progressive
non-viral liver diseases, today announced management will be
participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 19, 2018
at 10:20 a.m. Eastern Time
Webcast information for this event will be
available on the Investors page of Intercept's website at
http://ir.interceptpharma.com. Archived webcasts will be available
on Intercept's website for approximately two weeks.
About InterceptIntercept is a
biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat progressive
non-viral liver diseases, including primary biliary cholangitis
(PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing
cholangitis (PSC) and biliary atresia. Founded in 2002 in New York,
Intercept now has operations in the United States, Europe and
Canada.
CONTACT: For more information about Intercept Pharmaceuticals,
please contact:
Intercept Pharmaceuticals:Mark
Vignola+1-646-747-1000investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Investor inquiries: investors@interceptpharma.com
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Apr 2023 to Apr 2024